423749-16-0 Usage
Uses
Used in Fragrance Industry:
2,5-DIMETHYL-1-M-TOLYL-1H-PYRROLE-3-CARBALDEHYDE is used as a fragrance ingredient for its strong, sweet, and floral scent, adding depth and complexity to perfumes and cosmetic products.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 2,5-DIMETHYL-1-M-TOLYL-1H-PYRROLE-3-CARBALDEHYDE is used as an intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and medicinal compounds.
Used in Organic Synthesis:
2,5-DIMETHYL-1-M-TOLYL-1H-PYRROLE-3-CARBALDEHYDE is utilized as a key intermediate in the synthesis of a range of organic compounds, facilitating the creation of diverse chemical products.
Used in Chemical Research:
Due to its potential biological and pharmacological properties, 2,5-DIMETHYL-1-M-TOLYL-1H-PYRROLE-3-CARBALDEHYDE is used in chemical research to explore its applications and effects in various scientific and medical fields.
Check Digit Verification of cas no
The CAS Registry Mumber 423749-16-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,2,3,7,4 and 9 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 423749-16:
(8*4)+(7*2)+(6*3)+(5*7)+(4*4)+(3*9)+(2*1)+(1*6)=150
150 % 10 = 0
So 423749-16-0 is a valid CAS Registry Number.
InChI:InChI=1/C14H15NO/c1-10-5-4-6-14(7-10)15-11(2)8-13(9-16)12(15)3/h4-9H,1-3H3
423749-16-0Relevant academic research and scientific papers
A New FXR Ligand Chemotype with Agonist/Antagonist Switch
Helmst?dter, Moritz,Vietor, Jan,Sommer, Jana,Schierle, Simone,Willems, Sabine,Kaiser, Astrid,Schmidt, Jurema,Merk, Daniel
, p. 267 - 274 (2021/02/20)
Therapeutic modulation of the bile acid-sensing transcription factor farnesoid X receptor (FXR) is an appealing strategy to counteract hepatic and metabolic diseases. Despite the availability of several highly potent FXR agonists structural diversity of FXR modulators is limited, and new ligand scaffolds are needed. Here we report structure-activity relationship elucidation of a new FXR modulator chemotype whose activity can be tuned between agonism and antagonism by two minor structural modifications. Starting from a weak FXR/PPAR agonist, we have developed selective FXR activators and antagonists with nanomolar to low-micromolar potencies and binding affinities. The new FXR ligand chemotype modulates the FXR activity in the native cellular setting, is endowed with favorable metabolic stability, and lacks cytotoxicity. It valuably expands the collection of FXR modulators as a new scaffold for FXR-targeted drug discovery.
